Overview
Investors searching INJ vs USDAT usually want a clear market-cap and momentum snapshot. Injective prints $5.00 (+1.77%) while USDAT is at $1,867.53 (+0.00%), with volume edge currently on Injective.
Quick winners
Full comparison
| Metric | INJ | USDAT |
|---|---|---|
| Price | $5.00 | $1,867.53 |
| Market Cap | $490.41M | $106.96M |
| FDV | — | — |
| Volume 24h | $2.50M | $1.22M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 247.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | USDAT |
|---|---|---|
| 1H | — | — |
| 24H | +1.77% | +0.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | USDAT |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 65.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Automated technical notes for this pair highlight neutral conditions on INJ and bearish on USDAT. Volatility differences can amplify short-term gaps.
Fundamentals
| Metric | INJ | USDAT |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
USDAT
Pros and cons
Pros of Injective
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- Injective has an established coin page footprint on PEPS for continuous monitoring.
- INJ often anchors narratives that attract sustained media and analyst coverage.
Cons of Injective
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
Pros of USDAT
- USDAT can offer higher relative beta when market attention rotates toward its niche.
- Narrative optionality around USDAT can reprice quickly when catalysts appear.
- If technical momentum aligns, USDAT may outperform on medium-term windows.
Cons of USDAT
- Relative underperformance versus Injective can persist through entire market regimes.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
- Trend failures on USDAT often travel faster than on more established assets.
Which looks stronger right now?
Across winners above, no single coin dominates every column. Prefer scenarios: trend continuation favors the side with aligned momentum; mean-reversion favors the side stretched on RSI.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #99; USDAT shows $106.96M and #247. Where liquidity and flow matter, watch Injective. Where durability matters, watch Injective. AI composite scores (46.90/57.90) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or USDAT?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or USDAT?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and USDAT.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.